Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Sugrue

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Plos One|May 5, 2015
Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future InfectionsHayley Bennett, Phil McEwan, Daniel Sugrue, et al.
International Journal of Clinical Practice|December 17, 2020
Risk factors associated with the incidence and recurrence of hyperkalaemia in patients with cardiorenal conditionsEskinder Tafesse, Michael Hurst, Louise Hoskin, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|October 20, 2020
Serum potassium as a predictor of adverse clinical outcomes in patients with increasing comorbidity burdenEskinder Tafesse, Michael Hurst, Daniel Sugrue, et al.
Renal Failure|January 22, 2021
The effect of hyperkalemia and long inter-dialytic interval on morbidity and mortality in patients receiving hemodialysis: a systematic reviewDanai Bem, Daniel Sugrue, Ben Wilding, et al.
The Journal of General Virology|January 8, 2014
Human cytomegalovirus suppresses Fas expression and functionSepehr Seirafian, Virginie Prod'homme, Daniel Sugrue, et al.
Journal of Managed Care & Specialty Pharmacy|February 4, 2020
Estimating HIV Management and Comorbidity Costs Among Aging HIV Patients in the United States: A Systematic ReviewThomas Ward, Daniel Sugrue, Olivia Hayward, et al.
Advances in Therapy|January 12, 2021
Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature ReviewOliver Darlington, Carissa Dickerson, Marc Evans, et al.
BMC Rheumatology|February 4, 2021
Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational studyErnest Choy, Lara Groves, Daniel Sugrue, et al.
Plos Pathogens|April 16, 2015
Plasma membrane profiling defines an expanded class of cell surface proteins selectively targeted for degradation by HCMV US2 in cooperation with UL141Jye-Lin Hsu, Dick J H van den Boomen, Peter Tomasec, et al.
Plos Pathogens|May 3, 2014
Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradationCeri A Fielding, Rebecca Aicheler, Richard J Stanton, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Plos One|May 5, 2015
Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future InfectionsHayley Bennett, Phil McEwan, Daniel Sugrue, et al.
International Journal of Clinical Practice|December 17, 2020
Risk factors associated with the incidence and recurrence of hyperkalaemia in patients with cardiorenal conditionsEskinder Tafesse, Michael Hurst, Louise Hoskin, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|October 20, 2020
Serum potassium as a predictor of adverse clinical outcomes in patients with increasing comorbidity burdenEskinder Tafesse, Michael Hurst, Daniel Sugrue, et al.
Renal Failure|January 22, 2021
The effect of hyperkalemia and long inter-dialytic interval on morbidity and mortality in patients receiving hemodialysis: a systematic reviewDanai Bem, Daniel Sugrue, Ben Wilding, et al.
The Journal of General Virology|January 8, 2014
Human cytomegalovirus suppresses Fas expression and functionSepehr Seirafian, Virginie Prod'homme, Daniel Sugrue, et al.
Journal of Managed Care & Specialty Pharmacy|February 4, 2020
Estimating HIV Management and Comorbidity Costs Among Aging HIV Patients in the United States: A Systematic ReviewThomas Ward, Daniel Sugrue, Olivia Hayward, et al.
Advances in Therapy|January 12, 2021
Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature ReviewOliver Darlington, Carissa Dickerson, Marc Evans, et al.
BMC Rheumatology|February 4, 2021
Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational studyErnest Choy, Lara Groves, Daniel Sugrue, et al.
Plos Pathogens|April 16, 2015
Plasma membrane profiling defines an expanded class of cell surface proteins selectively targeted for degradation by HCMV US2 in cooperation with UL141Jye-Lin Hsu, Dick J H van den Boomen, Peter Tomasec, et al.
Plos Pathogens|May 3, 2014
Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradationCeri A Fielding, Rebecca Aicheler, Richard J Stanton, et al.
Pageof 2